healthcare

Melanoma Treatment Takes a Big Step Forward

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares jumped on Friday after the firm announced results from its mid-stage metastatic melanoma study at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. ...
Read Full Story »

Are Wright Medical Shareholders Getting Enough in the Stryker Acquisition?

Wright Medical Group N.V. (NASDAQ: WMGI) shares exploded on Monday after the announcement that the firm would be acquired by Stryker Corp. (NYSE: SYK). The boards of directors of both ...
Read Full Story »

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

RedHill Biopharma Ltd. (NASDAQ: RDHL) shares jumped early on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) approved Talicia for the treatment of Helicobacter pylori ...
Read Full Story »

Fitbit Set to Expand Its User Base as Google Acquisition Is Confirmed

The rumor mill sometimes is proven to be correct, and that's the case for Fitbit Inc. (NYSE: FIT) and Alphabet Inc. (NASDAQ: GOOGL). A press release issued on Friday morning ...
Read Full Story »

Multiple Sclerosis Treatment Wins Big FDA Approval

Biogen Inc. (NASDAQ: BIIB) and Alkermes PLC (NASDAQ: ALKS) announced an update from the U.S. Food and Drug Administration on Wednesday morning. The FDA approved Vumerity for the treatment of ...
Read Full Story »

Why Amgen Failed to Impress in Q3

When Amgen Inc. (NASDAQ: AMGN) released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 ...
Read Full Story »

Can Amgen Earnings Keep Up With Biogen?

Amgen Inc. (NASDAQ: AMGN) is set to report its most recent quarterly results after the closing bell on Tuesday. The consensus forecast calls for $3.53 in earnings per share (EPS) ...
Read Full Story »

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) reported their most recent quarterly results before the opening bell Tuesday. Despite some trepidation for the health care sector, ...
Read Full Story »

Merck and Pfizer Earnings: What to Expect

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Is Walgreens Getting Enough Out of Q4 Earnings?

Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The retailer said that it had $1.43 in earnings per share (EPS) ...
Read Full Story »

It’s Not the FDA Holding Back This New Pneumonia Treatment

Melinta Therapeutics Inc. (NASDAQ: MLNT) has announced that the U.S. Food and Drug Administration (FDA) has approved Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) ...
Read Full Story »

Major Biotechs See Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, October 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Cannabis Stocks a Little to Hazy for Short Sellers

Cannabis stocks had a huge showing on Wall Street last year. In fact, most of the news flow surrounding these stocks had investors pouring money into them. Some of the ...
Read Full Story »

Public Support for Marijuana Legalization Has Finally Stopped Rising

Many states have passed legislation legalizing marijuana use, in some cases for medical purposes and in others recreationally. The federal government has not passed any similar laws. If public opinion ...
Read Full Story »